Lyme disease, assay

Is a POC Diagnostic Test for Lyme Disease in the Near Future?

By MedTech Intelligence Staff
Lyme disease, assay

Researchers have developed a test that may be more sensitive that currently available lab tests.

Researchers at the National Institute of Allergy and Infectious Diseases have developed a rapid assay that, using a new set of biomarkers to detect Lyme disease, could be more sensitive than currently available diagnostics tests for the disease. The biomarkers are more effective at finding signs of Lyme disease infection in early stage examples, and it is speculated that this is due to the detection of antibodies that peak during the initial two to six weeks of infection, according to a National Institutes of Health news release.

For consideration by FDA, the assay will need to be further refined and tested, and the researchers are optimistic about its future development.

A study about the technology titled, “A Multiplex Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use”, was published this week in the Journal of Clinical Microbiology.

Related Articles

  • MilliporeSigma and Erbi Logos
    MilliporeSigma Acquires Erbi Biosystems

    The acquisition expands MilliporeSigma’s portfolio to a full range of bioreactors, from 2ml to 2000L, and adds to the company’s expertise in monoclonal antibody (mAb) process development.

  • Tim Brown
    Bridging the Design Development and Quality Management Chasm

    Bringing design and quality assurance processes together earlier in the device development process can reduce costs and nonconformances, while improving outcomes.

  • Avania and MAXIS logos
    CRO Avania Acquires MAXIS

    The acquisition brings MAXIS’ expertise in pre-clinical engineering, design validation and verification, regulatory affairs, field clinical services, and trial management to Avania’s contract research and MedTech development capabilities.

  • Veranex logo
    Veranex Acquires Medidee

    The acquisition expands Veranex’s European footprint as well as the scale and scope of its clinical studies capabilities.

About The Author

MedTech Intelligence